 |
|
Leukemia Trial Results
11. Palifermin Reduces Mouth Sores Caused by Blood Cancer Treatment
(Posted: 12/21/2004) - An experimental drug called palifermin (Kepivance®) reduced both the severity and the duration of sores and ulcers in the mouth in patients who received intensive chemotherapy and radiation to treat lymphoma and other cancers of the blood, according to a report in the Dec. 16, 2004, issue of the New England Journal of Medicine.
12. Alternate Drug Less Toxic, Less Effective Than Standard Treatment for ALL
(Posted: 05/20/2002, Reviewed: 03/15/2006) - Acute lymphoblastic leukemia (ALL) is the most common cancer in children. Now two new studies suggest that, given at the same dose, the standard E. coli form of the drug asparaginase -- a mainstay for more than 30 years in the treatment of ALL -- appears to be more effective, though more toxic, than another form known as Erwinia asparaginase.
13. Imatinib Mesylate (Gleevec™) Confirmed as More Effective Than Conventional Therapy for CML
(Posted: 05/20/2002, Reviewed: 12/20/2005) - Imatinib mesylate (Gleevec™) delayed progression of disease for longer, produced milder side effects, and resulted in a significantly better response than conventional therapy in patients with previously untreated chronic myelogenous leukemia (CML), according to a report in the March 13, 2003, issue of the New England Journal of Medicine. Preliminary findings from the study had been presented at a scientific meeting in May 2002.
14. Imatinib Mesylate (Gleevec™) Looks Even Better for Chronic Myelogenous Leukemia
(Posted: 03/14/2002, Reviewed: 12/20/2005) - Patients with chronic myelogenous leukemia (CML) responded well to the molecularly targeted drug imatinib mesylate (Gleevec™) and experienced few severe side effects, researchers with a large phase II study reported in the February 28, 2002, issue of the New England Journal of Medicine.
15. Higher Chronic Lymphocytic Leukemia Remissions with Fludarabine
(Posted: 11/08/2001, Reviewed: 03/15/2006) - Patients given fludarabine for chronic lymphocytic leukemia (CLL) have higher remission rates as compared with two other treatments, according to a study published in the October 15, 2001, issue of Blood.
< Previous 1 2 3 4 Next >
|
|
|
